TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25765724

Group type: EXPERIMENTAL
Intervention: Infarct diameter cut-off of 3 cm
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Infarct diameter cut-off of 3.5 cm
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Infarct diameter cut-off of 4 cm
Number of subjects: 238
Study: 25766045

Group type: EXPERIMENTAL
Intervention: Patients with TBI
Number of subjects: 439
Study: 25766093

Group type: EXPERIMENTAL
Intervention: 9-1-1 dispatcher assessment of OOHCA
Number of subjects: 2260

Group type: COMPARATOR
Intervention: Dispatchers suspected cardiac arrest in 490 cases not in cardiac arrest
Number of subjects: 2260
Study: 25766256

Group type: EXPERIMENTAL
Intervention: EGFR mutation analysis (exon 19 deletions and exon 21 L858R point mutation)
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: EGFR mutation analysis (exons 18, 20, and 21 excluding L858R)
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Clinical factors associated with EGFR mutations
Number of subjects: 1113
Study: 25766640

Group type: EXPERIMENTAL
Intervention: Anti-tumour necrosis factor (TNF) treatment
Number of subjects: 48
Study: 25766898

Group type: EXPERIMENTAL
Intervention: (11)C-PBR28 PET imaging using the SUVR method
Number of subjects: 57

Group type: COMPARATOR
Intervention: (11)C-PBR28 PET imaging using absolute quantitation (VT/fP)
Number of subjects: 57
Study: 25767565

Group type: EXPERIMENTAL
Intervention: CCO + SSD
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (supportive care + SSD)
Number of subjects: 55
Study: 25768439

Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa-mannose-sensitive hemagglutinin (PA-MSHA) 1 mg administered subcutaneously every other day and capecitabine 1000 mg/m2 orally twice a day for 2 weeks on, 1 week off.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa-mannose-sensitive hemagglutinin (PA-MSHA) with capecitabine in patients with moderate immune-related adverse events (irAEs).
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa-mannose-sensitive hemagglutinin (PA-MSHA) with capecitabine.
Number of subjects: 97
Study: 25768671

Group type: EXPERIMENTAL
Intervention: Baseline copeptin level >21.4 pmol/L
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Stimulated copeptin >4.9 pmol/L (at sodium levels >147 mmol/L)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Stimulated AVP >1.8 pg/mL
Number of subjects: 55
Study: 25768735

Group type: EXPERIMENTAL
Intervention: PASTOR (interprofessional biopsychosocial rehabilitation program)
Number of subjects: 536

Group type: COMPARATOR
Intervention: MOR (multidisciplinary orthopedic rehabilitation)
Number of subjects: 536
Study: 25769377

Group type: EXPERIMENTAL
Intervention: Adenosine-releasing silk
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Allopregnanolone (SAGE-547)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: AMP-X-0079
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Brivaracetam
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Cannabidiol
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Cannabidivarin
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 2-deoxy-glucose
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Ganaxolone
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Huperzine A
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Imepitoin
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: NAX 801-2
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Pitolisant
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: PRX 0023
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: SAGE-217
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Valnoctamide
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Sec-butyl-propylacetamide (SPD)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: VLB-01
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 130
Study: 25769620

Group type: EXPERIMENTAL
Intervention: Obinutuzumab-bendamustine (G-B)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Obinutuzumab-fludarabine-cyclophosphamide (G-FC)
Number of subjects: 41
Study: 25769789

Group type: EXPERIMENTAL
Intervention: mesenchymal stromal cell-based therapy
Number of subjects: 0
Study: 25769961

Group type: EXPERIMENTAL
Intervention: Nursing homes with 30 GPs or more/100 beds
Number of subjects: 6275

Group type: EXPERIMENTAL
Intervention: Residents aged ≥ 85 years
Number of subjects: 6275

Group type: EXPERIMENTAL
Intervention: Residents with dementia
Number of subjects: 6275

Group type: EXPERIMENTAL
Intervention: Residents with a statement of 'no psychotropic drug prescription' but had a prescription
Number of subjects: 6275
Study: 25770144

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injection (IVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not treated with IVR)
Number of subjects: 0
Study: 25770355

Group type: EXPERIMENTAL
Intervention: Sanfilippo Behavior Rating Scale (SBRS)
Number of subjects: 0
Study: 25770405

Group type: EXPERIMENTAL
Intervention: HeartWare HVAD System
Number of subjects: 382
Study: 25770408

Group type: EXPERIMENTAL
Intervention: Transvenous phrenic nerve stimulation
Number of subjects: 57
Study: 25770676

Group type: COMPARATOR
Intervention: Neoepitope concentrations in patients with idiopathic pulmonary fibrosis (n=189)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Baseline concentrations of neoepitopes in patients with progressive idiopathic pulmonary fibrosis (n=32)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Mean concentrations of C1M, C3M, C6M, and CRPM at baseline in patients with idiopathic pulmonary fibrosis (n=134)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Longitudinal concentrations of six neoepitopes in patients with progressive idiopathic pulmonary fibrosis (n=71)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Baseline concentrations of C1M and C3A
Number of subjects: 189

Group type: COMPARATOR
Intervention: Rate of change between baseline and 3 months of six neoepitopes
Number of subjects: 189

Group type: COMPARATOR
Intervention: Rate of change of CRPM greater than 0 ng/mL per month
Number of subjects: 189
Study: 25770690

Group type: COMPARATOR
Intervention: HbA1c levels <5.0, 5.0-5.6 (reference), 5.7-6.4
Number of subjects: 2519
Study: 25771041

Group type: EXPERIMENTAL
Intervention: 0.5% DHEA (prasterone) administered daily intravaginally for 52 weeks
Number of subjects: 521
Study: 25771402

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (standard dose: adult 400 mg daily; children 260 mg/m² daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (dose escalation regimen: adult 100 mg daily initial dose up to 200 mg daily maximum; children initial dose 65 mg/m² daily up to 130 mg/m² daily)
Number of subjects: 20
Study: 25771794

Group type: EXPERIMENTAL
Intervention: abiliti system (closed-loop gastric electrical stimulation)
Number of subjects: 34
Study: 25772026

Group type: EXPERIMENTAL
Intervention: Genetic profiling
Number of subjects: 0
Study: 25772191

Group type: EXPERIMENTAL
Intervention: Dietary intake of essential fatty acids (EFA)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Fat sources and fatty acid (FA) intake
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: FA compositions of serum lipids
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Phospholipid mead:arachidonic acid ratio
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Comparison of LA proportions in phospholipids
Number of subjects: 262
Study: 25772231

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (Neupro) as add-on to oral PD treatment for ≥1 month
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (Neupro)
Number of subjects: 147
Study: 25772541

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation (radiofrequency catheter ablation)
Number of subjects: 27
Study: 25772756

Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg QD with FOLFIRI
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg QD with FOLFOX
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg QD
Number of subjects: 119
Study: 25773763

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (1, 2, and 4 mg/24 h)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (4 mg/24 h)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 24
Study: 25773781

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study: 25773989

Group type: EXPERIMENTAL
Intervention: Patients with SCA
Number of subjects: 61
Study: 25774459

Group type: EXPERIMENTAL
Intervention: Marsh PK/PD model
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Schnider PK/PD model
Number of subjects: 12
Study: 25774664

Group type: EXPERIMENTAL
Intervention: Insulin-resistant group (HOMA-IR ≥2.6)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Insulin-sensitive group (HOMA-IR <2.6)
Number of subjects: 362
Study: 25775506

Group type: EXPERIMENTAL
Intervention: Food Record App (FRapp)
Number of subjects: 18
Study: 25775947

Group type: EXPERIMENTAL
Intervention: MCT + treatment-as-usual (TAU)
Number of subjects: 44

Group type: COMPARATOR
Intervention: treatment-as-usual (TAU)
Number of subjects: 44
Study: 25777337

Group type: EXPERIMENTAL
Intervention: Antiviral therapy with eltrombopag, pegylated interferon, and ribavirin
Number of subjects: 1268

Group type: COMPARATOR
Intervention: Cirrhosis-related thrombocytopenia
Number of subjects: 1268
Study: 25777344

Group type: EXPERIMENTAL
Intervention: Highly sensitive troponin (hsTnI)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: hsTnI serial measurements
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: hsTnI rising levels
Number of subjects: 99
Study: 25777345

Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg orally b.i.d. with bortezomib 1 mg/m(2) intravenously on days 1, 4, 8, and 11 every 21 days.
Number of subjects: 17
Study: 25777357

Group type: EXPERIMENTAL
Intervention: Energy preload (137 kcal)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Post-meal snack (430 kcal)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Maternal use of food as reward
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 236
Study: 25778529

Group type: EXPERIMENTAL
Intervention: Ex vivo fucosylation of cord blood cells using fucosyltransferase-VI and guanosine diphosphate fucose for 30 minutes.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Historical controls receiving double unmanipulated cord blood transplantation.
Number of subjects: 53
Study: 25778850

Group type: EXPERIMENTAL
Intervention: Rosuvastatin treatment for 18 months
Number of subjects: 86
Study: 25779580

Group type: EXPERIMENTAL
Intervention: Nonparametric population model with Bayesian adaptive control algorithm
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Using only trough concentrations for Bayesian posterior parameter values
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sample collected at optimal time of 4 h after dose, in addition to trough concentration
Number of subjects: 33
Study: 25779713

Group type: EXPERIMENTAL
Intervention: Power Doppler sonography
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gray-scale sonography
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vascularity measurement
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Wall thickness measurement
Number of subjects: 80
Study: 25780077

Group type: EXPERIMENTAL
Intervention: PCV13 vaccine
Number of subjects: 200
Study: 25780349

Group type: EXPERIMENTAL
Intervention: Contrast-associated acute kidney injury (CA-AKI) patients
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Higher APACHE II scores
Number of subjects: 335
Study: 25780518

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (HCG) stimulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no HCG stimulation)
Number of subjects: 60
Study: 25781361

Group type: EXPERIMENTAL
Intervention: 1-year outpatient intervention program based on exercise, behavior, and nutrition therapy
Number of subjects: 60
Study: 25782122

Group type: EXPERIMENTAL
Intervention: New oral anticoagulants (NOACs)
Number of subjects: 4100

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists
Number of subjects: 4100

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 4100
Study: 25782184

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent with biodegradable polymer
Number of subjects: 1356
Study: 25782401

Group type: EXPERIMENTAL
Intervention: Clinician assessment of dry eye severity using Dry Eye Workshop severity grading (levels 1-4)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Patient assessment using Ocular Surface Disease Index questionnaire
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Clinician assessment of treatment response using Clinical Global Impression scale
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Patient assessment of treatment response using Subject Global Assessment scale
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Correlation between clinician and patient assessments
Number of subjects: 466
Study: 25782757

Group type: EXPERIMENTAL
Intervention: Improved health status (SGRQ score change >4 units)
Number of subjects: 2138

Group type: EXPERIMENTAL
Intervention: Stable health status (SGRQ score change ≤4 units)
Number of subjects: 2138
Study: 25783622

Group type: EXPERIMENTAL
Intervention: High cfPWV
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Low PPA
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: High HR
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Low ADLs
Number of subjects: 682

Group type: COMPARATOR
Intervention: BP
Number of subjects: 682
Study: 25783834

Group type: EXPERIMENTAL
Intervention: Laparoscopic inguinal hernia repair
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Preoperative pain during sexual activity
Number of subjects: 160
Study: 25784682

Group type: EXPERIMENTAL
Intervention: Carfilzomib plus melphalan and prednisone (CMP) at the maximal tolerated dose (MTD) of 36 mg/m².
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Carfilzomib plus melphalan and prednisone (CMP) at the MTD of 36 mg/m².
Number of subjects: 68
Study: 25784749

Group type: EXPERIMENTAL
Intervention: Cumulative risk model using early neonatal risk factors
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Cumulative risk model using risk factors at 36 weeks' postmenstrual age
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Cumulative risk model using sociodemographic variables
Number of subjects: 1469
Study: 25784948

Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 80
Study: 25784955

Group type: EXPERIMENTAL
Intervention: Intervention arm (exclusive breastfeeding promotion by peer counsellors)
Number of subjects: 2579

Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 2579
Study: 25785226

Group type: EXPERIMENTAL
Intervention: Dietary polyunsaturated fatty acids (PUFAs) intake
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Dietary polyunsaturated fatty acids (PUFAs) intake in hormone therapy (HT) group
Number of subjects: 266

Group type: COMPARATOR
Intervention: Dietary polyunsaturated fatty acids (PUFAs) intake in non-hormone therapy (non-HT) group
Number of subjects: 266
Study: 25785487

Group type: EXPERIMENTAL
Intervention: Intrapartum oxytocin
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control (no intrapartum oxytocin)
Number of subjects: 98
Study: 25785995

Group type: EXPERIMENTAL
Intervention: pH1N1 vaccine (two double doses)
Number of subjects: 90
Study: 25786035

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists (MRAs), n=101
Number of subjects: 427

Group type: COMPARATOR
Intervention: No mineralocorticoid receptor antagonists (MRA-Neg), n=101
Number of subjects: 427
Study: 25786047

Group type: EXPERIMENTAL
Intervention: Hydrotherapy programme (16 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 20
Study: 25786252

Group type: EXPERIMENTAL
Intervention: High IGF1R gene expression
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Higher IGF1R expression
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: IGF1R expression
Number of subjects: 217
Study: 25786708

Group type: EXPERIMENTAL
Intervention: Vascular-targeted photodynamic therapy with TOOKAD(®) Soluble
Number of subjects: 0
Study: 25787057

Group type: EXPERIMENTAL
Intervention: DMT adherence measured by medication possession ratio (MPR) >0.9
Number of subjects: 3151

Group type: EXPERIMENTAL
Intervention: DMT adherence measured by medication possession ratio (MPR) >0.5-<0.9
Number of subjects: 3151

Group type: COMPARATOR
Intervention: DMT adherence measured by medication possession ratio (MPR) <0.5
Number of subjects: 3151
Study: 25787923

Group type: EXPERIMENTAL
Intervention: Ramucirumab 6, 8, or 10 mg/kg Q2W
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ramucirumab 15 or 20 mg/kg Q3W
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ramucirumab (all doses)
Number of subjects: 25
Study: 25787996

Group type: EXPERIMENTAL
Intervention: Arachidic acid (20:0) in the highest quartile
Number of subjects: 3179

Group type: EXPERIMENTAL
Intervention: Behenic acid (22:0) in the highest quartile
Number of subjects: 3179

Group type: EXPERIMENTAL
Intervention: Lignoceric acid (24:0) in the highest quartile
Number of subjects: 3179

Group type: EXPERIMENTAL
Intervention: Arachidic acid (20:0) after adjustment for triglycerides and palmitic acid
Number of subjects: 3179
Study: 25788178

Group type: EXPERIMENTAL
Intervention: Radiotherapy with concomitant thalidomide
Number of subjects: 43

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 43
Study: 25788458

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 4086
Study: 25788949

Group type: EXPERIMENTAL
Intervention: ragweed SLIT-T 6 Amb a 1-U
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: ragweed SLIT-T 12 Amb a 1-U
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: ragweed SLIT-T
Number of subjects: 337
Study: 25789557

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Micropore tape (Control)
Number of subjects: 34
Study: 25789614

Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperpnea (EVH)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Methacholine inhalation test (MIT)
Number of subjects: 52
Study: 25789989

Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE treatment) administered for 12 weeks
Number of subjects: 15
Study: 25790480

Group type: EXPERIMENTAL
Intervention: PRODIGI (autofluorescence imaging device)
Number of subjects: 40
Study: 25790767

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25790876

Group type: EXPERIMENTAL
Intervention: Carotid plaque burden (cPB)
Number of subjects: 5808

Group type: EXPERIMENTAL
Intervention: Coronary artery calcification (CAC)
Number of subjects: 5808

Group type: EXPERIMENTAL
Intervention: Composite of major adverse cardiac events (MACE)
Number of subjects: 5808

Group type: EXPERIMENTAL
Intervention: cPB and CAC
Number of subjects: 5808
Study: 25792386

Group type: EXPERIMENTAL
Intervention: EUS-FNA
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: CEH-EUS
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: ANN
Number of subjects: 167
Study: 25793018

Group type: EXPERIMENTAL
Intervention: Retinal venous pressure (RVP) measurement in patients with diabetic retinopathy (DR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retinal venous pressure (RVP) measurement in patients without diabetic retinopathy (nonDR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retinal venous pressure (RVP) measurement in healthy control subjects
Number of subjects: 0
Study: 25793152

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg weekly for 12 weeks
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 25793933

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine and albendazole (DEC/Alb) - single dose
Number of subjects: 79
Study: 25793960

Group type: EXPERIMENTAL
Intervention: Reformulated Flolan (epoprostenol sodium)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Currently marketed Flolan (epoprostenol sodium)
Number of subjects: 16
Study: 25794066

Group type: EXPERIMENTAL
Intervention: GEMOX-B (gemcitabine and oxaliplatin combined with bevacizumab)
Number of subjects: 28
Study: 25794243

Group type: EXPERIMENTAL
Intervention: Mobile Insulin Titration Intervention (MITI) - texting/phone call intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care arm - in-person clinic visits
Number of subjects: 0
Study: 25794535

Group type: EXPERIMENTAL
Intervention: Volasertib plus cisplatin (100 mg/m(2))
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Volasertib plus carboplatin (AUC6)
Number of subjects: 61
Study: 25795132

Group type: EXPERIMENTAL
Intervention: Gene-mediated cytotoxic immunotherapy (GMCI) with AdV-tk + prodrug in Arm A
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gene-mediated cytotoxic immunotherapy (GMCI) with AdV-tk + prodrug in Arm B
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Quality of life assessment in both arms
Number of subjects: 24
Study: 25795402

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m²) followed by Trabectedin (1.1 mg/m²) and Pegfilgrastim (6 mg) every 3 weeks for up to six cycles
Number of subjects: 109
Study: 25795432

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 0
Study: 25795637

Group type: EXPERIMENTAL
Intervention: Nintedanib 100-450 mg once daily (n = 40)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nintedanib 250 mg b.i.d. (n = 11)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nintedanib (various doses)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose (MTD)
Number of subjects: 51
Study: 25795722

Group type: EXPERIMENTAL
Intervention: Resimmune (2.5 - 11.25 μg/kg intravenous infusion over 15 minutes)
Number of subjects: 30
Study: 25795794

Group type: EXPERIMENTAL
Intervention: Agalsidase beta (1 mg/kg/2 weeks)
Number of subjects: 52
Study: 25795917

Group type: EXPERIMENTAL
Intervention: GSDI (Glaucoma Structural Diagnostic Index) using NFL, GCC, and disc variables
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: GSDI
Number of subjects: 166